Top Partnering Opportunities In Oncology: Broad Efficacy Leads To Broad Appeal
Partner-ready oncology assets cut across diverse fields, including drug conjugates, vaccines and cancer metabolism, with many likely to become part of early-stage deals with shared risk.
You may also be interested in...
The Cambridge, Mass.-based company slows R&D and lays off 17% of its work force, but prepares to build a sales staff as it continues to reap auspicious data on the kidney cancer drug.
With its cash position bolstered by a pair of public equity offerings this year, Endocyte Inc. is pressing ahead with its novel therapeutic and diagnostic platform, initiating late-stage trials in platinum-resistant ovarian cancer (PROC) and non-small-cell lung cancer (NSCLC), with a plan to seek a first approval in Europe.
Now that Seattle Genetics Inc. is making the transition into a commercial drug company with the FDA approval of its oncologic Adcetris, its success will depend on how effectively it can convince payers, patients and physicians that Adcetris is worth its premium price and how well it can extend the drug’s reach to larger patient markets.